In this large cohort of 13,559 patients with non-valvular afib in an integrated health care system, researchers determine the net clinical benefit of warfarin. They calculated benefit by the annual risk of CVA/emboli – the annual risk of intracranial hemorrhage (times a 1.5 “impact factor”). They found no net clinical benefit for those with CHADS2 scores of 0-1, but a 2.2% annual benefit for those with CHADS2 scores 4-6. The greatest benefit was found in those with a history of CVA and age >85 (abstract).
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc. Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them. If I am […]